City Therapeutics raises $99.5 million in Series B to advance RNAi drugs
BOSTON: City Therapeutics Inc., a biopharmaceutical company focused on next-generation RNA interference-based medicines, has raised $99.5 million in a Series B financing round, the company announced Tuesday. The round drew participation from new investors Viking Global Investors and Sofinnova Investments, alongside Casdin…